ARS Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share information)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue under collaboration agreements | $30 | $1,316 |
| Operating expenses: | ||
| Research and development (including related party amounts of $1,796 and $2,144, respectively) | 20,266 | 18,376 |
| General and administrative (including related party amounts of $940 and $603, respectively) | 47,284 | 18,456 |
| Total operating expenses | 67,550 | 36,832 |
| Loss from operations | (67,520) | (35,516) |
| Other income, net | 13,155 | 974 |
| Change in fair value of financial instruments | — | (140) |
| Net loss | $(54,365) | $(34,682) |
| Change in unrealized gains and losses on available-for-sale securities | (358) | 407 |
| Comprehensive loss | $(54,723) | $(34,275) |
| Net loss per share, basic and diluted | $(0.57) | $(0.87) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 95,215,322 | 39,956,043 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.